These findings prompted the approval of the first PARPi olaparib in Dicember 2014 as monotherapy for the treatment of patients with advanced ovarian cancer and BRCA1/2 germline mutations who have received three or more prior lines of chemotherapy [10–12]. The gene discussed is BRCA1; the disease is ovarian cancer.